Belite Bio develops oral therapies for degenerative retinal diseases with high unmet need. Its lead candidate, tinlarebant, is designed to reduce vitamin A–based toxin buildup linked to Stargardt disease type 1 and geographic atrophy in dry age-related macular degeneration. The company targets rare and progressive vision-loss conditions where approved treatment options remain limited.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -14.3 | — |
| Q2 2025 | 0 | — | -16.3 | — |
| Q3 2025 | 0 | — | -21.7 | — |
| Q4 2025 | 0 | — | -25.3 | — |
| Q1 2026 | 0 | — | -26.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AAON, Inc. (AAON), Erasca, Inc. (ERAS), Camtek Ltd. (CAMT), Travere Therapeutics, Inc. (TVTX), Credit Acceptance Corporation (CACC), Netskope, Inc. (NTSK)